Health News
Health News

Zabopegdutide Delivers 63% MASH Resolution in Phase 2 Trial

By Marcus Reid ·

What Makes This Data Compelling

D&D Pharmatech released final 48-week Phase 2 liver biopsy results for Zabopegdutide at the AASLD meeting in November 2026. The data showed a 62.5% MASH resolution rate in the treated group, compared to just 5.3% in the placebo arm. This statistically significant difference (p<0.001) marks a major milestone for metabolic dysfunction–associated steatohepatitis treatment.

The trial also measured fibrosis improvement without MASH worsening. Fifty percent of patients on Zabopegdutide showed fibrosis improvement, versus 15.8% in the placebo group (p=0.0). These results suggest the drug effectively addresses both inflammation and scarring in the liver.

Can This Drug Change the Treatment Landscape?

The MASH resolution figure stands out because it far exceeds historical benchmarks for existing therapies. Most current treatments achieve resolution rates below 30%. A 62.5% rate indicates Zabopegdutide may set a new standard for MASH management. The fibrosis improvement data further strengthens the case, showing the drug works on multiple pathological pathways simultaneously.

Clinicians are watching closely. If Phase 3 confirms these results, Zabopegdutide could become a first-line option for moderate-to-severe MASH patients. The company plans to expand the trial to larger, more diverse populations. Regulatory submissions are expected within the next 18 months.

What is Zabopegdutide? It is an experimental drug targeting MASH, a liver condition involving fat buildup, inflammation, and scarring. The Phase 2 trial tested its ability to resolve MASH and improve fibrosis.

Frequently Asked Questions

How does the 62.5% resolution rate compare to existing treatments? It is roughly double the resolution rates seen with current approved MASH therapies, which typically resolve the condition in fewer than 30% of patients.

When might Zabopegdutide reach the market? The company aims to file for regulatory approval within 18 months, assuming Phase 3 data supports the Phase 2 findings.